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Abstract
Aims/hypothesis The hormone betatrophin was recently de-
scribed as a potent stimulator of beta cell proliferation in
mice. Insulin resistance, but not insulin deficiency, caused
upregulation of betatrophin expression. If these findings were
found to be fully applicable in humans, this would open up the
possibility of future betatrophin treatment in type 1 diabetes.
The present study measured for the first time betatrophin
concentrations in humans and tested the hypothesis that
there would be no difference in circulating betatrophin
concentrations between patients with type 1 diabetes and
healthy individuals.
Methods Betatrophin concentrations in plasma of 33 patients
with type 1 diabetes and 24 age-matched healthy controls
were measured by ELISA. The study participants were
characterised for blood lipids, BMI, plasma glucose and
HbA1c, and, for the diabetic patients, their insulin require-
ments and any residual C-peptide concentrations.
Results Plasma betatrophin concentrations were normally
∼300 pg/ml, but were approximately doubled in patients with
type 1 diabetes. In the patients, there were no correlations
between betatrophin and age, blood lipids, BMI, glucose
control or insulin requirement, whereas in controls betatrophin
levels increased with age. BMI, blood pressure and triacyl-
glycerol, LDL-cholesterol and HDL-cholesterol levels were
similar in patients and healthy controls.
Conclusions/interpretation Circulating concentrations of
betatrophin are increased in type 1 diabetes in contrast with
what was recently described in an insulin-deficient mouse
model. However, increased betatrophin concentrations do
not protect against loss of C-peptide. Betatrophin treatment
in type 1 diabetes would therefore probably not be successful
without the use of supraphysiological doses or a combination
with immune regulatory treatment.
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Introduction
Despite intensive research, there is still no treatment available
to prevent loss of beta cells in type 1 diabetes. At disease
onset, generally 30–40% of beta cells remain. Most patients
have residual beta cell function for several years, and even up
to several decades later [1, 2]. This suggests the possibility of
ongoing renewal of beta cells in patients with type 1 diabetes,
or that some of these cells are resistant to immune destruction.
Betatrophin was recently described as a potent stimulator
of mouse beta cell proliferation [3]. Moreover, the secreted
protein has been detected in human plasma. When
overexpressed in mice, a 17-fold increase in beta cell prolif-
eration was observed [3]. Expression of betatrophin in liver
was upregulated in mouse models of type 2 diabetes and
during mouse pregnancy. However, specific depletion of beta
cells with diphtheria toxin did not cause upregulation, which
led the authors to conclude that betatrophin levels are regulat-
ed by insulin resistance and not insulin deficiency per se [3].
If these findings in mice were found to be fully applicable
in humans, this would open up the possibility of betatrophin
treatment in type 1 diabetes. The present study therefore tested
the hypothesis that there would be no difference in circulating
betatrophin concentrations between healthy individuals and
insulin-deficient patients with type 1 diabetes.
Methods
This study was approved by the Uppsala County regional
ethics board, and the reported investigations were carried out
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in accordance with the principles of the Declaration of
Helsinki as revised in 2000. All participants were supplied with
oral and written information about the study and gave written
consent. None had macrovascular complications and all were
normotensive without hypertensive treatment. All participants
were physically active non-smokers. Healthy age-matched con-
trols (n =24), without a first-degree relative with type 1 diabe-
tes, were recruited by advertising. Of 33 participants with type
1 diabetes, five had onset of diabetes within the preceding
2 years (mean duration 11.2±4 months, mean age at onset
24.6±2.7 years), whereas the remaining participants (n =28)
had a mean disease duration of 19±1.4 years and a mean age at
onset of 8.1±1.1 years.
Blood samples were collected after overnight fasting.
Betatrophin levels in plasma were determined with an ELISA
(Wuhan Eiaab Science,Wuhan, China; Catalogue No. E11644h).
This assay shows linearity for plasma samples when diluted from
1:2 to 1:16 with a correlation with the known concentration of
85–100%. Spiking with known concentrations of the protein
shows a recovery range of 89–105%, and no significant cross-
reactivity or interference with any other proteins has been ob-
served. All samples were analysed in duplicate. Samples with a
CV>15% were excluded. Betatrophin levels were confirmed by
western immunoblot using a betatrophin primary antibody
(Phoenix Pharmaceuticals, Phoenix, USA; WBK-051-55).
Plasma samples were depleted of albumin using AlbuVoid
Albumin Depletion Kit (Biotech Support Group, Monmouth
Junction, NJ, USA). Data were normalised for total protein
content. Other variables were analysed at the routine laboratory
at Uppsala University Hospital. In patients with undetectable
C-peptide concentrations by the standard method (i.e.
<0.003 nmol/l), an ultrasensitive C-peptide ELISA (detection
range 1.167–130 pmol/l) was used (Mercodia, Uppsala, Sweden).
Statistical analysis was performed using SigmaPlot 12.0. An
unpaired two-tailed t test was used to compare differences
between the groups. Correlations were determined by linear
regression using Pearson product moment correlation. All
values are given as mean ± SEM. p values <0.05 were consid-
ered significant.
Results
Betatrophin concentrations were approximately doubled in
patients with type 1 diabetes compared with controls
(Fig. 1a, b). The validity of the ELISA was confirmed by
correlation with signal obtained by western immunoblot
in 13 of the samples (Fig. 1c). There were no significant
differences in age, BMI, triacylglycerol concentration,
LDL-cholesterol concentration, HDL-cholesterol concentra-
tion or sex distribution between the two groups, although
triacylglycerol levels were, as a mean, 32% increased in the
patients with type 1 diabetes (p =0.20; Table 1). Fasting
plasma glucose concentrations were higher in the diabetic
patients, as were HbA1c and total cholesterol concentrations.
In the diabetic patients, there was a tendency to a negative
correlation between betatrophin concentration and BMI
(r2=0.14, correlation coefficient 0.29, p =0.10). There were
no correlations between betatrophin concentration and age
(r 2=0.05, p =0.52), age at onset of diabetes (r 2=0.03,
p =0.38), disease duration (r2=0.01, p =0.60), HbA1c (r
2=8×
10−12, p =1.0), fasting plasma glucose concentration (r2=0.06,
p =0.19), insulin requirement (r2=0.05, p =0.19), triacylglyc-
erol concentration (r2=0.002, p =0.89), LDL-cholesterol con-
centration (r2=0.04, p =0.21), HDL-cholesterol concentration
(r2=0.03, p =0.50) or total cholesterol concentration (r2=0.06,
p =0.27). In the healthy control group, there was a correlation
with age (r2=0.17, correlation coefficient 0.42, p =0.043),
whereas no correlation between betatrophin concentration and
BMI (r2=0.004, p =0.78), HbA1c (r
2=0.27, p =0.13), fasting
plasma glucose (r2=0.04, p =0.34), triacylglycerol concentra-
tion (r2=0.147, p =0.22), LDL-cholesterol concentration (r2=
0.073, p =0.40), HDL-cholesterol concentration (r2=0.0009,
p =0.93) or total cholesterol concentration (r2=0.017, p =0.68)
was observed.
All patients with type 1 diabetes were insulin-dependent,
and those within 2 years of onset still had detectable fasting
C-peptide concentrations (0.30±0.05 nmol/l). There was no
correlation between residual C-peptide levels and betatrophin
levels in the latter (p =0.89). We also found ten individuals
(36%) among the patients with longer duration of disease with
residual detectable fasting C-peptide (2.8±0.8 pmol/l), and in
this group also there was no correlation between betatrophin
and residual C-peptide level (p =0.61). When comparing in-
dividuals with residual C-peptide with those with undetectable
C-peptide, we found no difference in betatrophin concentra-
tion (638±212 vs 791±240 pg/ml), HbA1c (7.7±0.3% [60.3±
2.9 mmol/mol] vs 7.7±0.3% [60.5±3.3 mmol/mol]), insulin
requirement (0.70±0.07 vs 0.66±0.04 U [24 h]−1kg−1) or
BMI (24.2±0.7 vs 24.1±1.1 kg/m2).
Discussion
We describe for the first time betatrophin concentrations
in humans, and report that circulating concentrations of
betatrophin are increased in type 1 diabetes in contrast with
what has recently been described in an insulin-deficient mouse
model [3]. This indicates that there is already a potential
stimulus for beta cell proliferation present in type 1 diabetes,
but that this is not sufficient to counteract the decline in C-
peptide levels in the long run.
The reason for increased betatrophin levels in type 1 dia-
betes is at present not known. A feedback of insulin or
C-peptide deficiency, or increased blood glucose concentra-
tions, to increase beta cell mass by betatrophin secretion would
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be a favourable physiological mechanism, but the presence of
such a mechanism remains to be determined. Expression of the
betatrophin gene in mice has been described in several organs
including the liver, brown and white adipose tissue, adrenal
glands, duodenum and small intestine [3]. Induced insulin
resistance is a known potent stimulator of betatrophin expres-
sion in liver and fat tissue. It is possible therefore that the
increased betatrophin concentrations in patients with type 1
diabetes can be explained by insulin resistance. Although
insulin resistance is not part of the disease as in type 2 diabetes,
patients with type 1 diabetes can develop an increasing
requirement for insulin [4]. The characteristics of insulin resis-
tance are hypertension, abdominal obesity, increased
triacylglycerol concentrations and low HDL-cholesterol levels
[5]. In the type 1 diabetes group, there was indeed a tendency
for a weak correlation between betatrophin level and BMI, but
this was negative, and there was no correlation between
betatrophin and triacylglycerol level or HDL-cholesterol level.
Moreover, although triacylglycerol levels, as a mean, were
32% higher in participants with type 1 diabetes, neither
triacylglycerol level, nor BMI, blood pressure, LDL-cholesterol
or HDL-cholesterol level differed between the diabetic patients
and controls.
Betatrophin belongs to the family of angiopoietin-like pro-
teins. The gene encoding this protein is named C19orf80 , and
the nutritionally regulated secreting hormone has been given
many different names: lipasin, hepatocellular carcinoma-
associated protein-TD26, RIFL, angiopoietin-like protein-8
[6–8] and, most recently, betatrophin [3]. Overexpression of
betatrophin in mice leads to an increase in serum triacylglyc-
erol, and variations in the gene have been linked with blood
lipid levels in humans by genome-wide association studies
[6]. However, in our work, we observed no changes in blood
lipids that correlated with betatrophin levels. It cannot be
excluded that the mean increase in triacylglycerol levels ob-
served in the patients with type 1 diabetes would have been
statistically significant in a larger study.
In healthy controls, but not in the patients with type 1
diabetes, plasma betatrophin concentrations were, for un-
known reasons, higher in older individuals. It will therefore
be interesting in future studies to examine betatrophin con-
centrations in different age groups.
Post-mortem studies show conflicting results with regard to
whether beta cell replication occurs in type 1 diabetes [9, 10].
If present, increased levels of betatrophin may be a contribut-
ing factor. However, although betatrophin is increased in
plasma in patients with type 1 diabetes, its concentration does
not correlate with metabolic parameters. We cannot exclude
the possibility that increased betatrophin levels might have
had transient positive effects on beta cell mass early in the
disease, or that the decline in residual C-peptide may be
exaggerated in the absence of betatrophin. However, in the
long run, it does not protect from the progressive loss of
C-peptide secretion. An intervention in patients with
type 1 diabetes with betatrophin treatment might require
supraphysiological dosing as well as combination with im-
mune regulatory treatment.
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Fig. 1 Increased fasting plasma levels of betatrophin in patients with
type 1 diabetes. (a) Plasma concentrations of betatrophin in healthy
controls (HC, n =24) and patients with type 1 diabetes (T1D, n =33)
shown as mean ± SEM. (b) Scatter plot of the individual betatrophin
concentrations with mean ± SEM. (c) Correlation of betatrophin levels
obtained by western immunoblot with those obtained by ELISA in 13 of
the samples (six HC and seven patients with T1D) showing an r2 value of
0.69 (p =0.0004). Samples were normalised for total protein content,
values are arbitrary units (AU). *p <0.05
Table 1 Descriptive clinical data for healthy controls and patients with
type 1 diabetes
Variable Healthy controls (n =24) Patients (n =33)
Age (years) 25±0.8 26.5±1.1
% female 58 55
BMI (kg/m2) 23.1±0.51 24.1±0.53
Fasting glucose (mmol/l) 5.2±0.1 10.3±0.9*
HbA1c (%) 5.3±0.1 7.7±0.2*
HbA1c (mmol/mol) 33.9±0.64 60.5±2.1*
Cholesterol (mmol/l) 4.2±0.2 4.9±0.2*
Triacylglycerol (mmol/l) 0.81±0.09 1.07±0.1
HDL-cholesterol (mmol/l) 1.5±0.08 1.6±0.07
LDL-cholesterol (mmol/l) 2.4±0.2 2.7±0.2
All values are given as mean ± SEM. All blood samples were collected
after an overnight fast
*p <0.05
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